Cosette intros generic Cystadane

In an agreement with ANI, Cosette has obtained the U.S. marketing rights to betaine anhydrous for oral solution 180 gm, which is the generic of Recordati Rare Diseases’ Betaine.

Cosette has commenced shipping to customers this week.

“This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company,” said Apurva Saraf, president and CEO of Cosette."We stay true to our firm belief of innovating every day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”

[Read more: ANI intros generic Compazine]

Betaine is used by patients with homocystinuria, a rare genetic condition where too much homocysteine builds up in the body. This launch will provide patients with homocystinuria and the healthcare providers delivering care to those patients with a safe, efficacious and accessible treatment option, the company said.